Dr. Agarwal's Health Care Limited mature facilities grew 17.2%
Key highlights
- Dr. Agarwal's pre-FY23 facilities generated Rs 948 crore in H1 FY27, up 17.2% year-on-year.
- Dr. Agarwal's same-store sales growth was 17.7% in H1 FY27 and 18.8% in Q2 FY27.
- Dr. Agarwal's emerging facilities collectively contributed 21% of revenue in H1 FY27.
- Dr. Agarwal's management raised its FY27 target to 65 new facilities, including 55 surgical facilities.
powered by IRIS

In H1 FY27, Dr. Agarwal's reported Rs 948 crore of revenue from facilities operational before FY23, up 17.2% year-on-year and equal to 75% of group revenue. The company also recorded 17.7% same-store sales growth, while its emerging facilities collectively accounted for 21% of revenue.
Know Dr Agarwals Health Care inside out
Results, valuation, peers and who's buying, in one view.
How fast did Dr. Agarwal's existing facilities grow?
Dr. Agarwal's same-store sales growth was 17.7% in H1 FY27 and 18.8% in Q2 FY27, indicating that revenue growth extended beyond recently opened facilities. Management attributed the H1 increase to about 8% volume growth, comprising 7.5% outpatient department growth and 0.5% conversion growth, while value growth accounted for the remaining 9.5%.
Management said premiumisation contributed about 8 percentage points to H1 FY27 same-store sales growth, with price contributing the remaining 1.5 percentage points. The mature cohort, comprising facilities operational before FY23, generated Rs 948 crore during the six months and grew 17.2% year-on-year.
That established base accounted for 75% of group revenue, against total revenue from operations of Rs 1,269 crore in H1 FY27. Group revenue rose 28.7% from Rs 986 crore in H1 FY26, even as Dr. Agarwal's added 39 facilities, including 34 surgical facilities, during the first half.
How did Dr. Agarwal's facility vintages perform in H1 FY27?
Dr. Agarwal's FY24 facilities generated Rs 96 crore in H1 FY27, up 20.9% year-on-year, while FY25 facilities produced Rs 127 crore, up 67.8%. FY26 facilities generated Rs 71 crore and were described by management as being in the ramp-up phase, with no year-on-year growth figure disclosed.
Management said emerging facilities collectively represented 21% of H1 FY27 revenue and remained at an early stage of utilisation. This compares with the pre-FY23 cohort's 75% share, showing that the established network remained the main revenue source while newer facilities became a material part of the group mix.
The FY25 cohort's revenue base was higher than that of the FY24 cohort partly because it included an acquisition. Management said the Thind facility acquired in FY25 contributed about Rs 42 crore in H1 FY27 and stated that FY24 would show better performance if the acquired business were excluded from the FY25 comparison.
Got a follow-up? Ask IRIS
Which Dr. Agarwal's regions produced the fastest growth?
Dr. Agarwal's North region was the fastest-growing reported region in H1 FY27, with revenue rising 60% year-on-year to Rs 115 crore. The North represented 9% of group revenue, operated 36 facilities and had added 13 facilities during the year to date.
The South remained the largest regional business, generating Rs 790 crore, or 62% of group revenue, after 24.6% year-on-year growth in H1 FY27. Management linked Southern growth to expansion beyond cataract into refractive, retina and cornea services, as well as pharmacy and optical revenue streams.
The West generated Rs 195 crore, up 30% year-on-year, and represented 15% of group revenue, while the East delivered Rs 35 crore, also up 30%. Dr. Agarwal's added eight surgical Greenfield facilities in the West during H1 FY27, while Delhi NCR reached 15 facilities in 15 months after operations began in Q1 FY26.
What does Dr. Agarwal's expansion plan mean for newer facilities?
Dr. Agarwal's management raised its FY27 addition target to 65 facilities from 60, including 55 surgical facilities rather than the previously planned 40. Having opened 39 facilities in H1 FY27, including 34 surgical facilities, it plans to add another 26 facilities in the second half, including 21 surgical facilities.
The regional rollout plan calls for 25 additions in the South, 20 in the North, 15 in the West and five in the East during FY27. Management also raised planned FY27 capital expenditure to Rs 500 crore from about Rs 400 crore, citing the higher facility target and its expansion momentum.
Management said surgical facilities generate average monthly revenue of Rs 75 lakh to Rs 80 lakh and described Greenfield expansion as the company's predominant growth engine. Dr. Agarwal's nevertheless completed a two-facility Delhi acquisition whose last-12-month revenue was about Rs 13.5 crore and business earnings before interest, taxes, depreciation and amortisation, or EBITDA, were about Rs 7.16 crore.
New facilities are still generating start-up costs during ramp-up. Management said the FY26 and FY27 cohorts together incurred around Rs 42 crore of losses in the preceding six months, including Rs 20.12 crore for the FY26 cohort and Rs 18.2 crore for the FY27 cohort; meanwhile, H1 FY27 Ind AS EBITDA rose 27% to Rs 362 crore and the margin was 28.2%.
Conclusion
Dr. Agarwal's H1 FY27 results showed different growth rates across its network: the North expanded 60% to Rs 115 crore, compared with 24.6% growth in the Rs 790 crore South business. The combination of same-store volume and value growth, regional rollout and contributions from newer facilities supported group revenue growth of 28.7% to Rs 1,269 crore.
The next operating measure to watch is delivery against management's revised plan for 65 FY27 additions, with 26 facilities scheduled for H2 FY27. Management has set Rs 500 crore of FY27 capital expenditure and expects 55 surgical facilities for the full year, while the FY26 and FY27 cohorts' reported start-up losses remain a ramp-up issue to monitor.


